The pre-clinical studies for ImaginAb’s huJ591 Minibody / Prostate-Specific Membrane Antigen will be presented during a poster session at the World Molecular Imaging Congress in Kyoto, Japan by Dr. David Ho, Head of Pre-Clinical Development. This collaboration between UCLA and ImaginAb accelerates the advancement of ImaginAb’s PSMA imaging agent, set to fill an unmet clinical need in the diagnosis and treatment of prostate cancer. ImaginAb Inc. will also be showcasing its line of preclinical imaging agents and its clinical development pipeline in exhibitor booth 417 at WMIC.